' Compelling ' Regimen for Resectable Advanced-Stage Melanoma ' Compelling ' Regimen for Resectable Advanced-Stage Melanoma

Dr Weber reviews a new trial comparing neoadjuvant and adjuvant dual MEK/BRAF inhibition to standard of care in advanced resectable melanoma.Medscape Oncology
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news